A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

PHASE3CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

September 30, 1997

Study Completion Date

August 31, 1999

Conditions

Conduct DisorderOppositional Defiant DisorderDisruptive Behavior Disorder

Interventions

DRUG

Risperidone oral solution

All Listed Sponsors

lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY